Grants and Collaborations



Funding Grant name Grant Title Period PI
ANR TPS PATH Etudes structure-fonction de la voie de sécrétion protéique à deux partenaires chez les bactéries à Gram négatif : compréhension des mécanismes moléculaires du transport de protéines dans la superfamille Tps/Omp85 2007-2010 F. Jacob-Dubuisson
CPER INHboost Hypersensibilisation de M. tuberculosis à l’ioniazide, unantibiotique de première intention utilisé contre la tuberculose 2007-2010 A. Baulard
EU (FP7) TB-IRIS Pathogenesis and identification of predictive factors of TB IRIS in HIV patients under HAART 2007-2011 C. Locht
EU (FP7) HOMI-TB Host and microbial molecular dissection of the pathogenesis and immunity in tuberculosis 2008-2012 C. Locht
Lyon/Biopôle TBderma Mise au point, en phase preuve de concept, d’un test cutané de type intradermo-réaction destiné au dépistage de la tuberculose latente dans un environnement de soin hospitalier ou dispensaire 2008-2012 C. Locht
RIIP Proto TB Discovering the molecular basis of the evolutionary success of Mycobacterium tuberculosis by functional genomics of its putative ancestor Mycobacterium prototuberculosis 2009-2010 P. Supply
EU (FP7) TBPanNet European network for the study and clinical management of TB drug resistance 2009-2014 P. Supply
EU (FP7) New TBVac Identification and pre-clinical testing of new vaccine candidates for tuberculosis 2010-2013 C. Locht
ANR DYN FHA Two-partner secretion in bacteria : conformational dynamics of the ransporter FhaC 2010-2014 F. Jacob-Dubuisson
EU (EDCTP) TBTEA Collaboration and integration of tuberculosis vaccine trials in Europe and Africa 2011-2013 C. Locht
CPER TB Boost TB drug boost 2011-2013 A. Baulard
EU (FP7) PathoNGen Next generation genome based high resolution tracing of pathogens 2012-2016 P. Supply
COMU Lille TH-Hcimage Intracellular properties linked to mycobacterial virulence and persistance by high content imaging. 2013-2014 P. Supply
TBVI rHBHA Production of recombinant adjuvanted heparin-binding haemagglutinin TB vaccine for human testing 2013-2014 C. Locht
RIIP TB-LaTAS Tuberculose latente à Tunis, Antananarivo et Saint-Louis 2013-2015 N. Mielcarek
RIIP TBrat Development of a standardized rat model of Mycobacterium tuberculosis infection to screen protective efficacy of novel TB vaccine candidates 2014-2016 C. Rouanet
ANR Tea4Two Reprogrammation de la bioactivation des thioamides comme alternative antituberculeuse 2014-2017 A. Baulard
ANR MECA VENUS Mécanismes moléculaires de la transduction de signal par BvgS, un modèle de la famille de récepteurs kinases bactériens à domaines Vénus Flytrap 2014-2017 F. Jacob-Dubuisson
ILiAD NasVac Nasal vaccine against pertussis 2014-2018 C. Locht
EU (H2020) TBVac2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development 2015-2018 C. Locht
Thrasher pertvac Vaccine responses in infants after acellular pertussis vaccination during pregnancy in Thailand 2015-2018 C. Locht
CHU Lille TB-Leb Study of transmission and drug resistance of tuberculosis in resident and displaced populations in Lebanon by Next Generation Sequencing 2016-2018 P. Supply
EU (EDCTP) DIAMA Diagnostics of multidrug resistant tuberculosis in Africa 2016-2020 P. Supply
EU (IMI2) Periscope Pertussis correlates of protection Europe 2016-2021 C. Locht
ANR TB-emerg Birth of a killer : genetic factors and metabolic adaptations requried for the emergence of epidemic tuberculosis bacilli 2017-2020 P. Supply